Comparative Benchmarking
In the context of the broader market, LIMN competes directly with industry leaders such as APLT and KALA. With a market capitalization of $53.45M, it holds a leading position in the sector. When comparing efficiency, LIMN's gross margin of N/A stands against APLT's 100.00% and KALA's N/A. Such benchmarking helps identify whether Liminatus Pharma Inc is trading at a premium or discount relative to its financial performance.
